PharmaLedger.org
Réserver une consultation →

AstraTrace — CFO & Finance Leadership

Pharmaceutical shortage events have a direct financial cost.
Supply chain intelligence reduces that cost structurally.

AstraTrace is a predictable subscription — €499 to €15,000 per month depending on volume. The financial case is shortage prevention, recall cost reduction, and audit cost avoidance. The governance model is a Swiss nonprofit with no investor margin in your fees.

From €499 / monthSwiss nonprofitNo data monetisationPredictable subscription

Request a conversation

We respond within one business day.

No spam. No sales automation. Stefan responds personally.

COMMERCIAL MODEL
Subscription — no per-event overage below tier cap3 tiers · €499 to €15,000+ / monthSwiss nonprofit · Fees fund the platform, not investor returns

The financial case

Three cost categories that supply chain intelligence directly affects.

  • 01Shortage event costs — emergency logistics, expedited manufacturing, lost revenue. A pharmaceutical shortage event — whether caused by a supply chain disruption, a cold-chain excursion, or a distribution anomaly — carries direct financial consequences: emergency procurement premiums, expedited logistics costs, manufacturing schedule disruption, and in the worst cases, lost revenue from unavailable products. Early-warning shortage intelligence reduces the frequency and severity of these events by detecting signals before they become crises.
  • 02Recall execution costs — the faster you can locate affected batches, the lower the cost. When a recall is triggered, the cost of execution is directly correlated with how quickly the manufacturer can identify and locate all affected batches in the distribution chain. Manual batch tracing across a multi-tier supply chain takes days. AstraTrace reduces it to minutes — with a direct impact on recall logistics cost and health authority reporting timelines.
  • 03Audit and health authority reporting costs — manual reporting is expensive at scale. Health authorities are increasingly requesting supply chain transparency data. Producing these reports manually — compiling EPCIS data from multiple systems, market by market — is a significant operational cost at large MAHs. AstraTrace's Regulator Portal gives health authorities direct data access, converting a recurring manual reporting cost into a standing infrastructure cost.

Pricing — transparent, tiered, predictable

Three tiers. No hidden cost vectors.

TierMonthlyAnnualEPCIS eventsWhat's included
Starter€499€5,98825,000 / monthStandard dashboards, verifiable audit trail, 50 GTINs, 5 users
Professional€4,999€59,988500,000 / monthCustom reports, API access (standard rate limits), 1,000 GTINs, 25 users, cold chain add-on available
EnterpriseFrom €15,000From €180,000UnlimitedDedicated instance, custom integrations, unlimited GTINs & users, cold chain included, advanced CSRD analytics, high-volume API

What every tier includes

✓ Blockchain-verified audit trail

✓ GxP-qualified platform

✓ Daily Pulse reports

✓ Shelf-life analytics

✓ Implementation support

✓ Regulator Portal access (no charge to regulators)

Build vs buy

The true cost of building supply chain intelligence in-house.

In-house supply chain intelligence — true cost components

Data engineering team to build and maintain EPCIS aggregation pipelines. Dashboard and reporting infrastructure. Integration development with each downstream partner (distributors, health authorities) — bilaterally. Cold chain data ingestion and correlation layer. Ongoing maintenance as EPCIS standards and partner APIs evolve. GxP validation of a custom system. Standing internal team cost permanently.

Time to first useful output: typically 12–24 months. No network effect — only your own data, no downstream visibility.

AstraTrace — full cost

€4,999–€15,000+ per month depending on event volume. No internal engineering team required. Network participants (health authorities, other MAHs) already connected — no bilateral integration projects. Cold chain included in Enterprise. GxP validation documentation provided. CSRD analytics included in Enterprise.

Live in 6–10 weeks. Network visibility from day one — not just your own tier.

The nonprofit structure

No investor margin. No data monetisation. Fees that fund the work.

PharmaLedger Association is a Swiss nonprofit (CHE-178.875.143 MWST). There are no investors, no growth targets, and no mechanism by which commercial pressure translates into pricing pressure at renewal. Fees are set to cover platform infrastructure and operating costs. The Board includes representatives from GSK, MSD, and Takeda — organisations whose finance and procurement teams have completed their own vendor risk assessments for PLA.

0Investor return obligations
0Data monetisation arrangements
3Board members from Top-20 pharma

Also for your role

CanadaSupply ChainCFO & FinanceLegal & ComplianceRegulators

Common questions

Frequently asked questions

Is the monthly price fixed, or does it escalate based on actual event volumes?
Each tier has a defined EPCIS event cap per month. Within that cap, pricing is fixed. If your organisation's event volume grows beyond the tier cap, you move to the next tier — this is discussed and agreed in advance, not applied as a surprise overage charge. Enterprise tier has no event cap.
What is the contract term and exit provision?
Standard contract term is 12 months with annual renewal. Exit provisions are negotiated at contract stage with no lock-in beyond the contracted term. Standard contract terms are available before the commercial conversation.
Can you quantify the ROI on shortage prevention before we commit?
We do not publish quantified shortage prevention KPIs from the Alberta Health pilot until the data is formally validated — this is a deliberate accuracy commitment, not a gap. What we can provide in a commercial conversation: the cost structure of a typical pharmaceutical shortage event at MAH scale, the Alberta Health model and what it enables, and reference cases where supply chain intelligence reduced the time-to-detection of distribution anomalies. We do not ask you to commit on projected ROI figures we cannot yet validate.
Is PLA financially stable as a vendor for a long-term infrastructure commitment?
PLA is platform-revenue funded — not grant-dependent. Financial statements are audited annually by an independent auditor (Copartner Revision AG). Governance documentation and audited financials are available to finance teams conducting vendor due diligence on request.
Does the CSRD analytics capability justify the Enterprise premium for our sustainability reporting team?
AstraTrace Enterprise includes advanced CSRD analytics — supply chain emissions, logistics efficiency, and distribution carbon footprint reporting derived from the EPCIS data layer. For organisations with active CSRD reporting obligations under the EU Corporate Sustainability Reporting Directive, this converts a data collection burden into a standing data availability. Whether this justifies Enterprise vs Professional depends on your CSRD reporting scope — we scope this in the commercial conversation.

A predictable subscription. A nonprofit structure. The commercial terms sent before the call.

We send pricing, contract terms, and governance documentation in advance — so the commercial conversation starts from facts.

Request commercial terms overview